Omeprazole versus famotidine in the short-term treatment of duodenal ulcer disease.

Abstract

The efficacy and safety of omeprazole, in 241 patients with active recurrent duodenal ulcer from 21 Italian centres, was studied in a multicentre double-blind randomized trial comparing 20 mg omeprazole o.m. or 40 mg famotidine nocte with endoscopic examination, symptom recording, laboratory screening and gastrin assay. In a per protocol analysis, the duodenal ulcer healing rates for omeprazole and famotidine, documented by endoscopy, were 62% (68/109) and 33% (39/117) after 2 weeks of treatment (P less than 0.001), 92% (96/104) and 80% (86/108) cumulative after 4 weeks (P less than 0.05), and 99% (102/103) and 92% (96/104) after 6 weeks (P less than 0.05), respectively. The results of this trial demonstrate that 20 mg omeprazole o.m. is superior to 40 mg famotidine nocte in duodenal ulcer healing.

• Authors: G Delle Fave, B Annibale, M Franceschi, M Quatrini, M R Cassetta, A Torsoli
• Journal: Alimentary pharmacology & therapeutics (Aliment Pharmacol Ther) Vol. 6 Issue 4 Pg. 469-78 (Aug 1992) ISSN: 0269-2813 [Print] England
• PMID: 1420739 (Publication Type: Clinical Trial, Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)

Chemical References

• Gastrins
• Famotidine
• Omeprazole

Topics

• Abdominal Pain (drug therapy, etiology)
• Adult
• Aged
• Aged, 80 and over
• Dose-Response Relationship, Drug
• Double-Blind Method
• Duodenal Ulcer (complications, drug therapy)
• Evaluation Studies as Topic
• Famotidine (adverse effects, therapeutic use)
• Female
• Gastrins (blood)
• Humans
• Male
• Middle Aged
• Omeprazole (adverse effects, therapeutic use)